Investor Relations

Latest News

October 14, 2021 12:30pm EDT

Todos Medical to Conduct Webinar Highlighting the cPass SARS-COV-2 Neutralizing Antibody Test for AMDA, The Society for Post-Acute and Long-Term Care Medicine, on October 22, 2021 at 12:00 PM EDT

October 6, 2021 11:00am EDT

Todos Medical Announces Positive Data in Hospitalized and Outpatient Setting for TolloTest™, a Novel SARS-CoV-2 3CL Protease Biomarker Assay

October 5, 2021 6:00am EDT

UPDATE - Todos Medical Announces October Conference Calendar

October 4, 2021 7:30am EDT

Todos Medical Provides Update on COVID-19 Oral Antiviral 3CL Protease (Main Protease) Inhibitor Tollovir Clinical Development Program in Light of Molnupiravir Clinical Trial Data from Merck

View all news

Latest Presentation

Oct 1, 2021

Corporate Presentation

View Presentation

Upcoming Event

Oct 22, 2021 12:00 pm EDT

Webinar Highlighting the cPass SARS-COV-2 Neutralizing Antibody Test for AMDA, The Society for Post-Acute and Long-Term Care Medicine

Add to Calendar View All Events

Latest Financial Results

Q2 2021

Quarter Ended June 30, 2021

Earnings Release

PDF HTML

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending December 31, 2020

Company Overview

Todos Medical Ltd. is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer's disease through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company’s two cancer screening tests, TM-B1 and TM-B2, have received the CE mark. Todos owns 19.99% of Breakthrough Diagnostics, Inc., a joint venture with Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) that is developing the LymPro Test®, a blood test for diagnosing Alzheimer’s disease. Todos has exercised its option to acquire Breakthrough, and expects to close on that transaction in the first half of 2020. Todos has also entered into an exclusive option to acquire breast cancer blood testing company Provista Diagnostics, Inc. that is commercializing the Videssa® breast cancer blood test.

View Management Team View Board of Directors

IR Contacts

Company

Todos Medical Ltd.
121 Derech Menachem Begin, 30th Floor
Tel Aviv 6701203
Israel
T: +972-73-207-7259

Todos Medical U.S.A.
40 Wall Street, Suite 2702
New York, NY 10005
T: +1-917-983-4229